Cancer Immunotherapy Drug Discovery Outsourcing Market Research Report
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Cancer Immunotherapy Drug Discovery Outsourcing Market, Drug Type
7.1. Cancer Immunotherapy Drug Discovery Outsourcing Market, Drug Type, 2021-2028
7.1.1. Monoclonal Antibodies
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Immunomodulators
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Oncolytic Viral Therapies and Cancer Vaccines
7.1.3.1. Market Revenue and Forecast (2016-2028)
7.1.4. Others
7.1.4.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Cancer Immunotherapy Drug Discovery Outsourcing Market, Service Type
8.1. Cancer Immunotherapy Drug Discovery Outsourcing Market, Service Type, 2021-2028
8.1.1. Target Identification and Validation
8.1.1.1. Market Revenue and Forecast (2016-2028)
8.1.2. Lead Screening and Characterization
8.1.2.1. Market Revenue and Forecast (2016-2028)
8.1.3. Cell-Based Assays
8.1.3.1. Market Revenue and Forecast (2016-2028)
Chapter 9. Global Cancer Immunotherapy Drug Discovery Outsourcing Market, Cancer Type
9.1. Cancer Immunotherapy Drug Discovery Outsourcing Market, Cancer Type, 2021-2028
9.1.1. Lung
9.1.1.1. Market Revenue and Forecast (2016-2028)
9.1.2. Breast
9.1.2.1. Market Revenue and Forecast (2016-2028)
9.1.3. Colorectal
9.1.3.1. Market Revenue and Forecast (2016-2028)
9.1.4. Melanoma
9.1.4.1. Market Revenue and Forecast (2016-2028)
9.1.5. Prostate
9.1.5.1. Market Revenue and Forecast (2016-2028)
9.1.6. Head and Neck
9.1.6.1. Market Revenue and Forecast (2016-2028)
9.1.7. Ovarian
9.1.7.1. Market Revenue and Forecast (2016-2028)
9.1.8. Pancreatic
9.1.8.1. Market Revenue and Forecast (2016-2028)
Chapter 10. Global Cancer Immunotherapy Drug Discovery Outsourcing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.1.2. Market Revenue and Forecast, Service Type (2016-2028)
10.1.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.1.4.2. Market Revenue and Forecast, Service Type (2016-2028)
10.1.4.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.1.5.2. Market Revenue and Forecast, Service Type (2016-2028)
10.1.5.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.2. Europe
10.2.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.2.2. Market Revenue and Forecast, Service Type (2016-2028)
10.2.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.2.4.2. Market Revenue and Forecast, Service Type (2016-2028)
10.2.4.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.2.5.2. Market Revenue and Forecast, Service Type (2016-2028)
10.2.5.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.2.6.2. Market Revenue and Forecast, Service Type (2016-2028)
10.2.6.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.2.7.2. Market Revenue and Forecast, Service Type (2016-2028)
10.2.7.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.3. APAC
10.3.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.3.2. Market Revenue and Forecast, Service Type (2016-2028)
10.3.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.3.4.2. Market Revenue and Forecast, Service Type (2016-2028)
10.3.4.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.3.5.2. Market Revenue and Forecast, Service Type (2016-2028)
10.3.5.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.3.6.2. Market Revenue and Forecast, Service Type (2016-2028)
10.3.6.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.3.7.2. Market Revenue and Forecast, Service Type (2016-2028)
10.3.7.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.4. MEA
10.4.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.4.2. Market Revenue and Forecast, Service Type (2016-2028)
10.4.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.4.4.2. Market Revenue and Forecast, Service Type (2016-2028)
10.4.4.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.4.5.2. Market Revenue and Forecast, Service Type (2016-2028)
10.4.5.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.4.6.2. Market Revenue and Forecast, Service Type (2016-2028)
10.4.6.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.4.7.2. Market Revenue and Forecast, Service Type (2016-2028)
10.4.7.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.5. Latin America
10.5.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.5.2. Market Revenue and Forecast, Service Type (2016-2028)
10.5.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.5.4.2. Market Revenue and Forecast, Service Type (2016-2028)
10.5.4.3. Market Revenue and Forecast, Cancer Type (2016-2028)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, Drug Type (2016-2028)
10.5.5.2. Market Revenue and Forecast, Service Type (2016-2028)
10.5.5.3. Market Revenue and Forecast, Cancer Type (2016-2028)
Chapter 11. Company Profiles
11.1. Covance, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Explicyte
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Aquila BioMedical
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Horizon Discovery Group PLC
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Crown Bioscience, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Promega Corporation
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. HD Biosciences Co., Ltd.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. BPS Bioscience, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Genscript Biotech Corporation
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. DiscoverX Corporation
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Celentyx Ltd.
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. ImmunXperts SA
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
11.13. Personalis, Inc.
11.13.1. Company Overview
11.13.2. Product Offerings
11.13.3. Financial Performance
11.13.4. Recent Initiatives
11.14. STC Biologics
11.14.1. Company Overview
11.14.2. Product Offerings
11.14.3. Financial Performance
11.14.4. Recent Initiatives
11.15. Molecular Imaging, Inc
11.15.1. Company Overview
11.15.2. Product Offerings
11.15.3. Financial Performance
11.15.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers